The glucocorticoid receptor (GR) affects the transcription of genes involved in diverse processes including energy metabolism and the immune response through DNA-binding-dependent and -independent mechanisms. The DNA-bindingdependent mechanism occurs by direct binding of GR to glucocorticoid response elements (GREs) at regulatory regions of target genes; the DNA-binding-independent mechanism involves binding of GR to transcription factors and co-activators that in turn contact DNA. A small molecule that competes with GR for binding to GREs could be expected to selectively affect the DNA-binding-dependent pathway by interfering with the protein-DNA interface. We show that a DNA-binding polyamide that targets the consensus GRE sequence binds the glucocorticoid induced zipper (GILZ) GRE, inhibits expression of GILZ and several other known GR target genes, and reduces GR occupancy at the GILZ promoter. Genome-wide expression analysis of the effects of this polyamide on a set of glucocorticoid induced and repressed genes could help elucidate the mechanism of GR regulation for these genes.
Introduction
Glucocorticoids are a major subclass of steroid hormones known to modulate a large number of metabolic, cardiovascular, immune, and behavioral functions and play diverse roles in growth, development, and maintenance of basal and stress-related homeostasis.
Glucocorticoids exert a major influence on inflammatory processes and approximately 20% of the genes expressed in human leukocytes are regulated positively or negatively by glucocorticoids. 1 Glucocorticoids are among the most widely prescribed drugs worldwide, primarily used as anti-inflammatory and immunosuppressive agents. At the cellular level, the actions of glucocorticoids are mediated by a 94-kDa intracellular receptor protein, the glucocorticoid receptor (GR). The GR belongs to the superfamily of steroid/thyroid/retinoic acid receptor proteins that function as ligand-dependent transcription factors and binds with high affinity to glucocorticoids (GCs) such as cortisol and dexamethasone. As a member of the same class of transcription factors, GR is structurally similar to the androgen and progesterone receptors, containing a zinc-finger motif DNA binding domain, a dimerization domain, and a ligand binding domain. 2 In the absence of ligand, GR resides in the cytoplasm of cells as part of a complex of proteins including chaperon heat shock proteins (hsps) 90, 70, and 50. Hsp90 regulates ligand binding, as well as cytoplasmic retention of GR by exposing the ligand binding site and masking the two nuclear localization sequences contained within the protein. [3] [4] [5] Ligand binding releases GR from sequestration by cytoplasmic heat shock proteins 5 The glucocorticoid hormone, cortisol, passes through the plasma membrane into the cytoplasm where it binds to the specific, high-affinity glucocorticoid receptor (GR), releasing it from sequestration by heat shock proteins. The activated GR forms a homodimer and is translocated to the nucleus where the receptor complex binds to specific DNA-responsive elements to activate gene transcription.
Like other steroid hormone receptors, GR is known to modulate gene transcription via the binding of receptor dimers to specific palindromic sequences called glucocorticoid response elements (GREs), usually located in the cis-regulatory region of target genesthis mode of action is termed transactivation. Additionally, the GR has been shown to exert its actions through an indirect, non-DNA-binding mechanism, termed transrepression, in which transcriptional modulation is achieved through crosstalk between GR and other transcription factors such as nuclear factor-κB (NF-κB), 6 activator protein-1 (AP-1), 7, 8 Sma and Mad-related protein (Smad), and signal transduction and activator of transcription (STAT). 9 This protein-protein cross talk does not require the DNA-binding activity of the GR, as GR mutants that are deficient in dimerization function have been shown to lose DNA binding ability as well as simple GRE-mediated transcription function but retain their transrepression activity. 7, 10 Because many GR target genes are immune modulators, synthetic GR agonists such as dexamethasone are among the most effective anti-inflammatory drugs available for the treatment of a variety of chronic and acute inflammatory diseases. Unfortunately, because of the functions of other GR target genes, long term treatment with corticosteroids results in metabolic and behavioral derangements that can be treatment limiting. While the GR targets involved in inflammatory and immune regulation have not been comprehensively defined, there is a great deal of evidence suggesting that transrepression-that is, GR interaction with NF-kB and/or AP-1 and the subsequent suppression of their target genesis the major mechanism by which glucocorticoids achieve their desired anti-inflamatory effect. 8, 11, 12 An understanding of the mechanisms of GR activity on target genes has been explored using a variety of approaches including microarray analysis, 13, 14 ChIP-scanning, 15 and modulation of GR activity using siRNA, 16 genetic mutants, 7 and ligands with modified 46 structures. 17 However, these methods would not be expected to explicitly differentiate between the direct and indirect mechanisms of GR action. A small molecule that competes with GR for binding to the consensus GRE could be expected to specifically disrupt GR-DNA binding and be used as a tool to identify GR target genes whose regulation mechanism depends on a direct protein-DNA interface. This differentiation of mechanisms of GR target gene regulation could contribute to efforts to develop more specific GR modulators that retain immunosuppressant functions while minimizing side effects resulting from other GR targets. 18 Py-Im polyamides have previously been used to modulate gene expression in cell culture via inhibition of the transcription factor-DNA interface of both hypoxia inducible factor 19, 20 and androgen receptor 21 to their respective DNA response elements. Because Py-Im polyamides can be selectively programmed to recognize the known DNA-binding sequence of the GR, interruption of the GR-DNA binding interaction by polyamides represents a unique opportunity to inhibit the DNA-binding-dependent activity of endogenous GR while leaving the protein-protein-mediated activity unaffected (Figure 2. 3). Top: Direct mechanism is dependent upon GR-DNA binding at the GR response element (GRE). Bottom: Indirect mechanism is dependent upon GR binding to another protein, indicated here as a general transcription factor TF (with binding site TF response element TFRE). A sequence-specific polyamide designed to bind to the GRE but not to the TFRE would alter gene expression controlled by the DNA-binding-dependent but not the DNA-binding-independent mechanism.
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In this study we designed a polyamide targeted to the sequence 5'-WGWWCW-3' (where W represents either a T•A or an A•T base pair), found in the consensus GRE, with the goal of disrupting GR-GRE binding (Figure 2.3A, polyamide 1) . This polyamide binds the two known GREs found in the promoter of the well-characterized glucocorticoid-induced leucine zipper (GILZ) gene, inhibits expression of GILZ and 17% of transcripts induced by dexamethasone in cultured alveolar epithelial cells (A549), and reduces GR occupancy at the GILZ promoter in vivo. A "mismatch" polyamide that targets the sequence 5'-WGWCGW-3' (Figure 2 .3A, polyamide 2) is used as a control for non-GRE binding polyamide effects. The subset of GR-regulated genes that are uniquely affected by the GRE-targeted polyamide may represent a set of genes that are regulated by GR through direct GR-GRE binding. 
Results
I. Binding affinities of Py-Im polyamides to GRE1 and GRE2 of the GILZ promoter
II. Electrophoretic mobility shift assay (EMSA)
The effects of polyamides 1 and 2 on the binding of recombinant human glucocorticoid receptor to an oligo containing the GRE1 site of the GILZ promoter were measured by an electrophoretic mobility shift assay (Figure 2 A) Induction of GILZ mRNA in the presence of mifepristone (mif), 1 and 2, as measured by quantitative real-time PCR. Polyamide 1 inhibits expression of GILZ mRNA up to 65% at 5 and 10 µM while polyamide 2 shows no effect. 3 µM mifepristone control inhibits expression up to 79%. Error bars represent SD. B) Chromatin immunoprecipitation assays with anti-GR or mock antibody treatment expressed as fold-enrichment (specific/mock) of DNA sequences at the GILZ promoter. GR occupancy at the GILZ promoter is decreased in the presence of 1 (10 µM) and to a lesser extent by 2. Error bars represent SD. C) WST-1 colorimetric assay of cell viability and proliferation. Cells were treated for 24 and 48 hours with either polyamide 1 or 2 and subsequently assayed for cell viability and proliferation by measuring the absorbance of the dye at A max of 450 nm on a multiwell plate reader.
IV. Genome-wide microarray analysis
Global effects of polyamides 1 and 2 and the GR antagonist mifepristone on gene expression in dexamethasone-stimulated A549 cells were monitored with Affymetrix high-density Human Genome U133 Plus 2.0 arrays, which interrogate >50,000 transcripts.
Of these transcripts, 431 were affected greater than 2-fold by dexamethasone compared to non-induced control, with 323 transcripts induced while 108 were repressed. An agglomerative clustering analysis of the transcripts affected by dexamethasone demonstrates distinctive patterns of genes that are GC-responsive and GR-mediated but have differential response to treatment by polyamide 1 and 2 (Figure 2 .8A) at 5 µM concentration. 
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The GR antagonist mifepristone abolishes the activity of GR and therefore was used as a control to identify those transcripts that were affected by a GR-related mechanism. 431 transcripts were either induced or repressed by 2-fold or greater (p < 0.01) by dexamethasone treatment. Of these, the effects of dexamethasone were abolished by simultaneous treatment by 3 µM mifepristone for 252 transcripts, indicating that these 252 were a result of GR activity (Figure 2.8B) . For 76 transcripts of this set of 252, the effects of dexamethasone treatment were abolished by polyamide 1 to a greater extent than by polyamide 2, indicating a sequence-specific polyamide effect on those transcripts (Figure 2.8C ). This set of 76 transcripts corresponds to 67 genes, listed in Table 2 We anticipate that the regulation of these genes by GR involves a direct GR-GRE
interaction. In order to analyze the potential GRE sequence-specific role of polyamide treatment within this subset of GR-regulated genes, those genes that showed similar effect from both polyamides 1 and 2 were considered to be non-GRE-specific effects and were 55 not included among those analyzed. Many of the genes identified by the microarray as dexamethasone-responsive are consistent with those previously identified in this cell line. 15 A list of the effect of all treatment conditions on the GR-regulated genes is available in the Materials and Methods section of this chapter.
Discussion
A mechanistic understanding of cell signaling is fundamental to the development of improved medicines and diagnostics. Towards this end, the functions of individual biomolecules and their involved pathways have been explored using both biological and chemical methods. Genetic approaches include gene knockouts, dominant negative proteins, and siRNA to affect the activity of selected genes. Chemical approaches have utilized pre-existing, designed, or discovered small molecules that perturb a particular protein or specific protein-protein interaction, and have been employed successfully to characterize cell signaling pathways. [23] [24] [25] The elucidation of transcription factor, coactivator, and corepressor activation, their gene targets, and mechanisms of activity is a focus of intense research interest.
Genome-wide, high-throughput approaches including mRNA microarray analysis, 26 ChIP-chip, [27] [28] [29] and more recently ChIP-sequencing 30 have been used to define the targets of transcription factors. Specific protein-DNA interactions are the interfaces where information from protein signaling is converted into programs of gene expression. Used in the context of genome-wide analysis, small molecules that perturb this interface in a predictable manner could become useful tools for understanding gene expression.
Programmable, DNA-binding Py-Im polyamides offer a chemical approach to perturbing protein-DNA interactions that could be used for characterization of transcription factor-DNA interactions. We have reported previously that Py-Im polyamide 1, which targets 5'-WGWWCW-3', inhibits androgen receptor (AR) binding to its consensus sequence 5'-GGTACAnnnTGTTCT-3'. 22 As members of the same class of transcription factors, AR and GR share highly conserved DNA-binding domains, similar consensus sequences and transactivation mode of action. However, each acts within their individual biological contexts and responds to distinct chemical stimuli. The use of polyamide 1 in the context of disrupting the GR-GRE interface offers additional perspective in the mechanistic study of GR gene-regulatory action and its dual transactivation/transrepression mechanisms.
Because of the central role of GR in multiple inflammatory response pathways and its role as a drug target, mechanistic studies of GR-modulated gene expression are a growing field of study. However, the multiple mechanisms by which GR mediates gene expression makes identification of GR target genes a challenge. 9, 18, 31 The complex transcriptional activity of the GR involves DNA-binding-dependent as well as DNA-binding-independent mechanisms that result in both gene activation as well as repression. In general the most well-understood mechanism is that by which genes are activated by direct DNA binding of GR to a GRE in the regulatory region of target genes followed by recruitment of coactivators and the general transcriptional machinery. Another well-documented, though less understood mechanism is the transrepression mechanism, in which GR exerts its influence indirectly by binding to other proteins and transcription factors leading to the repression of genes controlled by those proteins. Intriguingly, an increasing body of evidence indicates that much of the anti-inflammatory activity of GCs is mediated by the transrepression mechanism, a finding that has been attributed largely to the repression of key inflammatory transcription factors including AP-1 and NF-κB. [6] [7] [8] Meanwhile, many of the reported side effects of GC treatment have been attributed to transactivation mechanism. 32 induced GR occupancy of the GILZ promoter is reduced, suggesting that it is polyamide 58 occupancy at this site that is responsible for the lowered mRNA expression levels.
A control polyamide 2 targeted at a different sequence, 5'-WGWCGW-3', shows reduced affect on GR promoter occupancy and no effect on GILZ gene transcription.
The established ability of polyamide 1 to disrupt the GR-GRE interaction for GILZ led us to a genome-wide search for other transcriptional events that are interrupted sequence-specifically. Affymetrix microarrays interrogating >50,000 transcripts were chosen to examine the global effect of polyamides 1 and 2 at 5 µM concentration on dexamethasone-treated cells. The GR antagonist mifepristone was used as a control in order to isolate which of the dexamethasone-responsive transcripts result from GR activity.
These conditions isolated 252 genes which were considered genuine GR-modulated GC-affected transcripts. Both polyamides had a similar and modest effect on cell proliferation under these experimental conditions.
In order to tease out which of these effects is due to a binding event at a 5'-WGWWCW-3' sequence corresponding to a GRE, we have eliminated genes from the list that were affected by polyamide 2, as both the footprinting and ChIP data shows that it is possible that this compound may have an effect on genes whose promoters contain a 5'-WGWCGW-3' site.
Of the list of 252 GR-modulated transcripts, treatment with polyamide 1 had a unique effect on 170 transcripts over treatment with polyamide 2. This left us with a final list of 170 transcripts whose expression is confidently affected both by GR as well as our sequence-specific small molecule. Of this final list of confidently interrogated transcripts we find 76 transcripts, corresponding to 67 genes, which are identified as genes whose expression was modulated by polyamide 1. We believe this list of genes to represent 67 genes that are regulated by direct GR-DNA interactions. While little information exists in the literature linking glucocorticoid response with these genes, we note that several genes with known functional GRE binding sites are included in the list ( There is still very little known about many of the genes that are affected by glucocorticoids, including which genes are activated as a result of transrepressed mechanisms or transactivated mechanisms. The lack of identified GREs to be found in the literature complicates the search for genes that are regulated by the transactivation mechanism. DNA-binding polyamides represent a unique approach to differentiating the transrepression from transactivation activity of the GR-the potential to selectively block the protein-DNA interactions of endogenous GR while leaving the protein-protein interactions unaffected. This approach is limited by the target site degeneracy of both the polyamide as well as GR, effects of specific polyamide-DNA binding on programs of other transcription factors, and non-specific effects of polyamides that are independent of sequencespecific polyamide-DNA binding. Small molecules that affect specific GR-protein interactions represent a complementary approach that is as yet unexplored. It is our hope that the list of genes provided by this study serves as a guide towards genes that necessitate further exploration in the search to selectively regulate the transactivation mechanism of glucocorticoid response. ii. Plasmid preparation Plasmid pGR_GILZ was constructed by ligating the following hybridized inserts (a 78-bp sequence from the GILZ promoter containing GRE1 and GRE2) into the BamHI / HindIII polycloning site in pUC19: 
Materials and Methods
Materials
iv. Quantitative DNase I footprint titrations
All reactions were carried out in a volume of 400 mL according to published protocols.
Polyamides were equilibrated with the radiolabeled DNA for 14 h prior to DNase I cleavage at 23 ºC. Quantitation by storage phosphor autoradiography and determination of equilibrium association constants were as previously described. 35 v. Electrophoretic mobility shift assay (EMSA)
The h, the medium was replaced with F12-K containing 10% charcoal-stripped FBS, 4 mM penicillin/streptomycin, and polyamides or mifepristone at the designated concentrations.
Cells were grown for an additional 48 h and then treated with 100 nM dexamethasone for 6 h. (Figure 2.9) . The medium was removed, cells were washed with ice-cold PBS and immediately lysed with RLT buffer from an RNeasy kit (Qiagen). Further RNA isolation was carried out with the RNeasy kit as described in the manufacturer's manual. The isolated total RNA was quantified. The yields were 12-15 μg per well. 
Real-time quantitative RT-PCR:
Analysis was performed using the GILZ gene primers described below, purchased from Integrated DNA Technologies Quantitative real-time RT-PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) following the manufacturer's suggested protocol. Temperature cycling and detection of the SYBR Green emission were performed with an ABI 7300 real-time instrument using Applied Biosystems Sequence
Detection System version 1.2. Statistical analysis was performed on three independent experiments. mRNA of the genes of interest were measured relative to β-glucuronidase as an endogenous control. Primer sequences were designed using Primer3. 36 To amplify the 97-bp fragment from the 3'-translated region of GILZ:
Forward primer: 5'-CTCCCCGTTTGTTTTTCTCA -3'
Reverse primer: 5'-TGCTCCTTCAGGATCTCCAC -3'
To amplify the β-glucuronidase gene as an endogenous control: qPCR using primers targeted to the GILZ promoter were used to assess enrichment of bound fragments as compared with mock-precipitated (no antibody) controls. PCRs were monitored with SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300 qPCR instrument. Primer sequences, described below, were designed using Primer3. 36 Detailed procedure can be found in Nicholas Nickols' PhD dissertation. 40 To amplify the 88-bp fragment from the 5'-promoter region of GILZ:
Forward primer: 5'-GCACTGATTCATGGGTACTGG -3'
Reverse primer: 5'-ACCAACTCAGGACCAAAGGAG -3'
ix. Analysis of Gene Expression with Oligonucleotide Microarrays.
A549 cells were plated in 12-well plates at a density of 40-50 x 10 3 cells per well.
Media conditions, polyamide treatment, time course, and dexamethasone stimulation were identical to the conditions described above for qPCR and ChIP. Mifepristone was added 68 at the same time as polyamide was added. RNA was isolated as previously described. The
RNA was submitted to the Millard and Muriel Jacobs Gene Expression Facility at the
California Institute of Technology where labeled mRNA was hybridized to Affymetrix high-density Human Genome U133 Plus 2.0 arrays according to established protocols.
Gene expression was analyzed by using Resolver (Rosetta Biosoftware, Seattle, WA). Data were uploaded to the Gene Expression Omnibus repository (accession no. GSE17307). 
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